- Home
- BALY vs NUVB Comparison
BALY vs NUVB Comparison
Compare BALY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BALY
- NUVB
- Stock Information
- Founded
- BALY 2004
- NUVB 2018
- Country
- BALY United States
- NUVB United States
- Employees
- BALY N/A
- NUVB N/A
- Industry
- BALY Hotels/Resorts
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- BALY Consumer Discretionary
- NUVB Health Care
- Exchange
- BALY Nasdaq
- NUVB Nasdaq
- Market Cap
- BALY 709.6M
- NUVB 774.1M
- IPO Year
- BALY N/A
- NUVB N/A
- Fundamental
- Price
- BALY $16.26
- NUVB $2.21
- Analyst Decision
- BALY Hold
- NUVB Strong Buy
- Analyst Count
- BALY 7
- NUVB 6
- Target Price
- BALY $18.00
- NUVB $7.67
- AVG Volume (30 Days)
- BALY 363.4K
- NUVB 1.6M
- Earning Date
- BALY 02-19-2025
- NUVB 03-03-2025
- Dividend Yield
- BALY N/A
- NUVB N/A
- EPS Growth
- BALY N/A
- NUVB N/A
- EPS
- BALY N/A
- NUVB N/A
- Revenue
- BALY $2,481,783,000.00
- NUVB $2,162,000.00
- Revenue This Year
- BALY $3.06
- NUVB N/A
- Revenue Next Year
- BALY N/A
- NUVB $374.06
- P/E Ratio
- BALY N/A
- NUVB N/A
- Revenue Growth
- BALY 2.80
- NUVB N/A
- 52 Week Low
- BALY $9.74
- NUVB $1.67
- 52 Week High
- BALY $18.38
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- BALY 47.14
- NUVB 37.58
- Support Level
- BALY $15.54
- NUVB $2.16
- Resistance Level
- BALY $17.66
- NUVB $2.38
- Average True Range (ATR)
- BALY 1.16
- NUVB 0.12
- MACD
- BALY 0.15
- NUVB 0.00
- Stochastic Oscillator
- BALY 81.72
- NUVB 16.13
About BALY Bally's Corporation
Ballys Corp is a casino entertainment company with a growing omni-channel presence. It currently owns and manages 15 casinos across 10 states, a golf course in New York, a horse racetrack in Colorado, and has access to OSB licenses in 18 states. It also owns Bally's Interactive International, formerly Gamesys Group, a online gaming operator, Bally Bet, a sports betting platform, and Bally Casino, a iCasino platform. The Company's casino operations include approximately 15,300 slot machines, 580 table games, and 3,800 hotel rooms.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).